Table.3.
Patient, disease, and treatment factors, and the weighted median cumulative incidence of patients retransitioning
| Characteristic | Studies, n (n = 37) |
Patients, n (n = 8555) |
Median cumulative incidence of patients retransitioninga |
|---|---|---|---|
| Patient factors | |||
| Age | |||
| Only adult patients | 22 | 7324 | 6.6 (5.7–9.1) |
| All age categories | 15 | 1231 | 8.9 (6.9–22.8) |
| Disease factors | |||
| Indication | |||
| Rheumatic disease | 22 | 4573 | 15.1 (5.4–16.0) |
| Inflammatory bowel disease | 7 | 1556 | 6.6 (0.9–8.3) |
| Multiple indications | 4 | 2330 | 16.2 (13.7–18.8) |
| Other | 4 | 96 | 17.7 (7.2–33.1) |
| Disease stability | |||
| Only stable patients | 15 | 2085 | 7.0 (1.5–7.1) |
| All patients | 22 | 6470 | 13.7 (8.0–21.4) |
| Treatment factors | |||
| Type of TNFα inhibitor | |||
| Etanercept | 11 | 3705 | 6.5 (3.7–8.0) |
| Infliximab | 23 | 4525 | 6.7 (6.7–14.2) |
| Adalimumab | 2 | 180 | 3.1 (1.2–5.1) |
| Multiple | 1 | 145 | 4.1 (NA) |
| Minimum duration use originator | |||
| Only patients with minimum duration of use | 13 | 3525 | 18.3 (7.4–19.2) |
| All patients | 24 | 5030 | 15.1 (13.2–16.9) |
NA not applicable, TNF tumor necrosis factor
aData are presented as weighted % (interquartile range)